ESCRS - Rhexis-fixated intraocular lens

Rhexis-fixated intraocular lens

Capsule-fixated lens achieves stable rotation and centration in international trial

Rhexis-fixated intraocular lens
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Friday, March 1, 2019
Gerd Auffarth MD
The rhexis-fixated FEMTIS (Oculentis) intraocular lens achieved very good visual acuity and excellent centration and rotational stability in an international multi-centre study, reports Gerd Auffarth MD, University Eye Clinic of Heidelberg, Heidelberg, Germany. “Compared to historical data, the FEMTIS IOL was superior to the conventional in-the-bag implanted IOLs,” Dr Auffarth told the 36th Congress of the ESCRS in Vienna, Austria. The study took place in eight clinics in Germany, the UK, Spain and Andorra and involved 360 eyes with cataract and expected postoperative corneal astigmatism of under -1.00D. All underwent implantation of a monofocal FEMTIS IOL following cataract extraction surgery performed with femtosecond laser-assisted capsulotomy. The FEMTIS IOL Foldable one-piece IOL is composed of Hydrosmart, a UV absorbing co-polymer consisting of acrylates with a hydrophobic surface. The lens has a biconvex optic with an aspheric posterior surface. It has a modified plate haptic design with four additional haptics for rhexis-fixation. The mean logMAR best-corrected distance visual acuity improved from 0.25 preoperatively to 0.00 at six-to-eight weeks, 0.00 at six months and -0.04 at 12 months postoperatively. In terms of refractive predictability, Dr Auffarth noted that patients ended up slightly hyperopic on average, with a mean spherical equivalent of +0.35D at 12 months. However, 85% were within 0.75D of emmetropia and 68% were within 0.5D and 41% were within 0.25D. The A constant of the IOL has since been adjusted to improve accuracy. The FEMTIS study group assessed the centration, tilt and rotational stability using images they obtained with microscope, slit lamp and Scheimpflug camera (Pentacam, Oculus). They analysed the data using a dedicated analysis program developed by Heidelberg Institute of Applied Mathematics. Their assessment showed that the average IOL-rotation was 0.78° at 12 months postoperatively, compared to values ranging from 2.7° to 5.3° in historical series. The mean IOL decentration was 0.07mm at 12 months postoperatively, compared to values ranging from 0.19mm to 0.23mm in historical series. In addition, the mean tilt at 12 months was 0.45° compared to tilt of 2.0° to 3.0°. Regarding posterior capsule opacification, the mean PCO grade was 0.7% at six months postoperatively and 1.1% at 12 months postoperatively. “The rhexis-fixated FEMTIS IOL shows very good results regarding the uncorrected and best-corrected distance visual acuity and excellent rotational as well as centration behaviour,” Dr Auffarth concluded. Gerd Auffarth: Gerd.Auffarth@med.uni-heidelberg.de
Tags: cataract surgery, IOL, rhexis-fixated lens
Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...